146 related articles for article (PubMed ID: 16723225)
1. Design, synthesis, and SAR studies of novel and highly active tri-cyclic HIV integrase inhibitors.
Jin H; Cai RZ; Schacherer L; Jabri S; Tsiang M; Fardis M; Chen X; Chen JM; Kim CU
Bioorg Med Chem Lett; 2006 Aug; 16(15):3989-92. PubMed ID: 16723225
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of 5-(1-H or 1-alkyl-5-oxopyrrolidin-3-yl)-8-hydroxy-[1,6]-naphthyridine-7-carboxamide inhibitors of HIV-1 integrase.
Melamed JY; Egbertson MS; Varga S; Vacca JP; Moyer G; Gabryelski L; Felock PJ; Stillmock KA; Witmer MV; Schleif W; Hazuda DJ; Leonard Y; Jin L; Ellis JD; Young SD
Bioorg Med Chem Lett; 2008 Oct; 18(19):5307-10. PubMed ID: 18774711
[TBL] [Abstract][Full Text] [Related]
3. A series of 5-aminosubstituted 4-fluorobenzyl-8-hydroxy-[1,6]naphthyridine-7-carboxamide HIV-1 integrase inhibitors.
Guare JP; Wai JS; Gomez RP; Anthony NJ; Jolly SM; Cortes AR; Vacca JP; Felock PJ; Stillmock KA; Schleif WA; Moyer G; Gabryelski LJ; Jin L; Chen IW; Hazuda DJ; Young SD
Bioorg Med Chem Lett; 2006 Jun; 16(11):2900-4. PubMed ID: 16554152
[TBL] [Abstract][Full Text] [Related]
4. 1,3,4-Oxadiazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 2: SAR of the C5 position.
Johns BA; Weatherhead JG; Allen SH; Thompson JB; Garvey EP; Foster SA; Jeffrey JL; Miller WH
Bioorg Med Chem Lett; 2009 Mar; 19(6):1807-10. PubMed ID: 19217284
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells.
Zhuang L; Wai JS; Embrey MW; Fisher TE; Egbertson MS; Payne LS; Guare JP; Vacca JP; Hazuda DJ; Felock PJ; Wolfe AL; Stillmock KA; Witmer MV; Moyer G; Schleif WA; Gabryelski LJ; Leonard YM; Lynch JJ; Michelson SR; Young SD
J Med Chem; 2003 Feb; 46(4):453-6. PubMed ID: 12570367
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and antiviral activity of 7-benzyl-4-hydroxy-1,5-naphthyridin-2(1H)-one HIV integrase inhibitors.
Boros EE; Edwards CE; Foster SA; Fuji M; Fujiwara T; Garvey EP; Golden PL; Hazen RJ; Jeffrey JL; Johns BA; Kawasuji T; Kiyama R; Koble CS; Kurose N; Miller WH; Mote AL; Murai H; Sato A; Thompson JB; Woodward MC; Yoshinaga T
J Med Chem; 2009 May; 52(9):2754-61. PubMed ID: 19374386
[TBL] [Abstract][Full Text] [Related]
7. A potent and orally active HIV-1 integrase inhibitor.
Egbertson MS; Moritz HM; Melamed JY; Han W; Perlow DS; Kuo MS; Embrey M; Vacca JP; Zrada MM; Cortes AR; Wallace A; Leonard Y; Hazuda DJ; Miller MD; Felock PJ; Stillmock KA; Witmer MV; Schleif W; Gabryelski LJ; Moyer G; Ellis JD; Jin L; Xu W; Braun MP; Kassahun K; Tsou NN; Young SD
Bioorg Med Chem Lett; 2007 Mar; 17(5):1392-8. PubMed ID: 17194584
[TBL] [Abstract][Full Text] [Related]
8. Repositioning HIV-1 integrase inhibitors for cancer therapeutics: 1,6-naphthyridine-7-carboxamide as a promising scaffold with drug-like properties.
Zeng LF; Wang Y; Kazemi R; Xu S; Xu ZL; Sanchez TW; Yang LM; Debnath B; Odde S; Xie H; Zheng YT; Ding J; Neamati N; Long YQ
J Med Chem; 2012 Nov; 55(22):9492-509. PubMed ID: 23098137
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of novel tricyclic HIV-1 integrase inhibitors by modification of its pyridine ring.
Metobo SE; Jin H; Tsiang M; Kim CU
Bioorg Med Chem Lett; 2006 Aug; 16(15):3985-8. PubMed ID: 16723226
[TBL] [Abstract][Full Text] [Related]
10. The use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 1: Establishing the pharmacophore.
Johns BA; Weatherhead JG; Allen SH; Thompson JB; Garvey EP; Foster SA; Jeffrey JL; Miller WH
Bioorg Med Chem Lett; 2009 Mar; 19(6):1802-6. PubMed ID: 19217781
[TBL] [Abstract][Full Text] [Related]
11. Discovery and structure-activity relationship studies of a unique class of HIV-1 integrase inhibitors.
Dayam R; Sanchez T; Neamati N
ChemMedChem; 2006 Feb; 1(2):238-44. PubMed ID: 16892356
[TBL] [Abstract][Full Text] [Related]
12. QSAR study of substituted 1,3,4-oxadiazole naphthyridines as HIV-1 integrase inhibitors.
Ravichandran V; Shalini S; Sundram K; Sokkalingam AD
Eur J Med Chem; 2010 Jul; 45(7):2791-7. PubMed ID: 20347187
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of substituted 4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxamides, novel HIV-1 integrase inhibitors.
Langford HM; Williams PD; Homnick CF; Vacca JP; Felock PJ; Stillmock KA; Witmer MV; Hazuda DJ; Gabryelski LJ; Schleif WA
Bioorg Med Chem Lett; 2008 Jan; 18(2):721-5. PubMed ID: 18078751
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of novel N-hydroxy-dihydronaphthyridinones as potent and orally bioavailable HIV-1 integrase inhibitors.
Johnson TW; Tanis SP; Butler SL; Dalvie D; Delisle DM; Dress KR; Flahive EJ; Hu Q; Kuehler JE; Kuki A; Liu W; McClellan GA; Peng Q; Plewe MB; Richardson PF; Smith GL; Solowiej J; Tran KT; Wang H; Yu X; Zhang J; Zhu H
J Med Chem; 2011 May; 54(9):3393-417. PubMed ID: 21446745
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of novel nitrogen-containing polyhydroxylated aromatics as HIV-1 integrase inhibitors from caffeic acid phenethyl ester.
Wang P; Liu C; Sanches T; Zhong Y; Liu B; Xiong J; Neamati N; Zhao G
Bioorg Med Chem Lett; 2009 Aug; 19(16):4574-8. PubMed ID: 19625188
[TBL] [Abstract][Full Text] [Related]
16. N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[1,2-a]pyrimidine-2-carboxamides a novel class of potent HIV-1 integrase inhibitors.
Petrocchi A; Jones P; Rowley M; Fiore F; Summa V
Bioorg Med Chem Lett; 2009 Aug; 19(15):4245-9. PubMed ID: 19523819
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and anti-integrase activity of catechol-DKA hybrids.
Maurin C; Bailly F; Mbemba G; Mouscadet JF; Cotelle P
Bioorg Med Chem; 2006 May; 14(9):2978-84. PubMed ID: 16412645
[TBL] [Abstract][Full Text] [Related]
18. New hexahydrodiazocino-naphthyridine triones as HIV-1 integrase inhibitors: WO2008048538 A1.
Cotelle P
Expert Opin Ther Pat; 2009 Jan; 19(1):87-93. PubMed ID: 19441900
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of dual inhibitors of HIV reverse transcriptase and integrase: introducing a diketoacid functionality into delavirdine.
Wang Z; Vince R
Bioorg Med Chem; 2008 Apr; 16(7):3587-95. PubMed ID: 18314335
[TBL] [Abstract][Full Text] [Related]
20. A series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-[1,6]naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and viral replication in cells.
Embrey MW; Wai JS; Funk TW; Homnick CF; Perlow DS; Young SD; Vacca JP; Hazuda DJ; Felock PJ; Stillmock KA; Witmer MV; Moyer G; Schleif WA; Gabryelski LJ; Jin L; Chen IW; Ellis JD; Wong BK; Lin JH; Leonard YM; Tsou NN; Zhuang L
Bioorg Med Chem Lett; 2005 Oct; 15(20):4550-4. PubMed ID: 16102965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
